Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

Polypoidal Choroidal Vasculopathy

  • Home
  • Polypoidal Choroidal Vasculopathy
Predictors of 1-Year Visual Outcome in Central-Involving Submacular Hemorrhage Secondary to Neovascular AMD
Posted innews Ophthalmology

Predictors of 1-Year Visual Outcome in Central-Involving Submacular Hemorrhage Secondary to Neovascular AMD

Posted by MedXY By MedXY 05/27/2026
This study found that younger age, better baseline vision, smaller hemorrhage size, and thicker subfoveal choroid predicted better 1-year visual outcomes after fovea-involving submacular hemorrhage from nAMD or PCV.
Read More
High-Dose Aflibercept 8 mg Demonstrates Sustained Visual Gains and Durability in Polypoidal Choroidal Vasculopathy
Posted innews Ophthalmology

High-Dose Aflibercept 8 mg Demonstrates Sustained Visual Gains and Durability in Polypoidal Choroidal Vasculopathy

Posted by MedXY By MedXY 12/24/2025
This post hoc analysis of the PULSAR trial reveals that aflibercept 8 mg provides noninferior visual outcomes and comparable anatomic regression to standard 2 mg dosing in PCV patients, while allowing for significantly extended treatment intervals and reduced injection burden.
Read More
  • Decoding Registry-Based Randomised Controlled Trials: Advancing Clinical Evidence Through Standardisation and Taxonomy
  • Optimizing Type 2 Diabetes Treatment: Comparing Precision Approaches in the TriMaster Trial
  • Cardiac Resynchronization Therapy With or Without Defibrillator in Nonischemic Cardiomyopathy: Evidence Synthesis and Clinical Implications from DECIDE-CRT and Related Studies
  • Decoding the U-Shaped Relationship Between Left Ventricular Size and Mortality in Heart Failure Patients
  • Impact of Combined Transcatheter Mitral and Tricuspid Edge-to-Edge Repair in Patients with Moderate Mitral Regurgitation and Severe Tricuspid Regurgitation
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology health heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health metformin Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prostate cancer public health quality of life randomized clinical trial randomized controlled trial randomized trial risk stratification SGLT2 inhibitors stroke type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in